Fibrosis-Cirrhosis Index (FCI index) that was developed at Functional Genomics Lab at Centre of Excellence in Molecular Biology back in 2011 has now become an important tool in assessing the progression of fibrosis caused by HCV. These researchers not only developed the index but also proved it to be more efficient as compared to readily available serum indexes, including AAR, APRI, FI, and FIB-4. The efficacy of the FCI index was further proven when the researchers from the Department of Public Health in the USA and California University conducted a clinical trial in San Francisco to compare two treatment methods for HCV among people who inject drugs. Through out the trial, the researchers used the FCI index, developed at CEMB, to assess 12-week response, and reinfection rate. This FCI index proved to be highly efficient in differentiating the progression of fibrosis caused by HCV in the trial participants.